Carbamazepine extended-release capsules in bipolar disorder

Neuropsychiatric Disease and Treatment

Volumn 2, Issue 1, 2006, Pages 3-11

  Weisler, Richard H ^a,b,c  

^a DUKE UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c NONE   (United States)

Author keywords

Bipolar disorder; Carbamazepine; Extended release; Mania

Indexed keywords

CARBAMAZEPINE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LITHIUM SALT; MOOD STABILIZER; PLACEBO; VALPROIC ACID;

AGRANULOCYTOSIS; APLASTIC ANEMIA; ATAXIA; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFUSION; COORDINATION DISORDER; DIPLOPIA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; MANIA; META ANALYSIS; MIXED MANIA AND DEPRESSION; MONOTHERAPY; NAUSEA; OPEN STUDY; PHARMACODYNAMICS; PRURITUS; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; SUSTAINED DRUG RELEASE; SYSTEMATIC REVIEW; VERTIGO; VOMITING;

EID: 33646050008     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. [APA] American Psychiatric Association. 2000. Diagnostic and statistical manual of mental disorders. 4th ed (text revision). Washington, DC: American Psychiatric Association.
2. [APA] American Psychiatric Association Steering Committee on Practice Guidelines. 2002. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry, 159:1-50.
3. Angst J. 1998. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord, 50:143-51.
4. Baldessarini RJ, Tondo L, Suppes T, et al. 1996. Pharmacological treatment of bipolar disorder throughout the life-cycle. In Shulman K, Tohen M, Kutcher S (eds). Bipolar disorder through the life-cycle. New York: John Wiley & Sons. p 299-338.
5. Ballenger JC, Post RM. 1978. Therapeutic effects of carbamazepine in affective illness: a preliminary report. Commun Psychopharmacol, 2:159-75.
6. Belmaker RH. 2004. Bipolar disorder. N Engl J Med, 351:476-86.
7. Bowden CL, Brugger AM, Swann AC, et al. 1994. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA, 271:918-24.
8. Canger R, Altamura AC, Belvedere O, et al. 1990. Conventional vs controlled-release carbamazepine: a multicentre, double- blind, crossover study. Acta Neurol Scand, 82:9-13.
9. Davis JM, Janicak PG, Hogan DM. 1999. Mood stabilizers in the prevention of recurrent affective disorders: a meta-analysis. Acta Psychiatr Scand, 100:406-17.
10. Dean BB, Gerner D, Gerner RH. 2004. A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in bipolar disorder. Curr Med Res Opin, 20:139-154.
11. Denicoff KD, Smith-Jackson EE, Disney ER, et al. 1997. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry, 58:470-8.
12. Dilsaver SC, Swann SC, Chen YW, et al. 1996. Treatment of bipolar depression with carbamazepine: results of an open study. Biol Psychiatry, 40:935-7.
13. Emilien G, Maloteaux JM, Seghers A, et al. 1996. Lithium compared to valproic acid and carbamazepine in the treatment of mania: a statistical meta-analysis. Eur Neuropsychopharmacol, 6:245-52.
14. Ficker D. 2004. Switching from immediate-release to extended-release carbamazepine capsules: safety and tolerability. Annual Meeting of the American Epilepsy Society. 2004 December 5-7; New Orleans, LA, USA.
15. Garnett WR, Levy B, McLean AM, et al. 1998. Pharmacokinetic evaluation of twice-daily extended-release carbamazepine (CBZ) and four-times-daily immediate-release CBZ in patients with epilepsy. Epilepsia, 39:274-9.
16. Ginsberg LD. 2004a. Efficacy and safety of ERC-CBZ in the treatment of bipolar II disorder. 56th Institute on Psychiatric Services. 2004 October 6-10; Atlanta, GA, USA.
17. Goodwin FK. 2003. Rationale for using lithium in combination with other mood stabilizers in the management of bipolar disorder. J Clin Psychiatry, 64(Suppl 5):18-24.
18. Goodwin FK, Jamison KR. 1990. Maintenance medical treatment. In Goodwin FK, Jamison KR (eds). Manic-depressive illness. New York: Oxford University Pr. p 665-724.
19. Goodwin FK, Murphy DL, Bunney WE, Jr. 1969. Lithium-carbonate treatment in depression and mania. A longitudinal double-blind study. Arch Gen Psychiatry, 21:486-96.
20. Gould TD, Manji HK. 2002. Signaling networks in the pathophysiology and treatment of mood disorders. J Psychosom Res, 53:687-97.
21. Gould TD, Quiroz JA, Singh J, et al. 2004. Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers. Mol Psychiatry, 9: 734-755.
22. Greenberg RN. 1984. Overview of patient compliance with medication dosing: a literature review. Clin Ther, 6:592-9.
23. Greil W, Kleindienst N, Erazo N, et al. 1998. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol, 18:455-60.
24. Haefeli WE, Meyer PG, Luscher TF. 1994. Circadian carbamazepine toxicity. Epilepsia, 35:400-2.
25. Hoppener RJ, Kuyer A, Meijer JW, et al. 1980. Correlation between daily fluctuations of carbamazepine serum levels and intermittent side effects. Epilepsia, 21:341-50.
26. Jamison KR, Akiskal HS. 1983. Medication compliance in patients with bipolar disorder. Psychiatr Clin North Am, 6:175-92.
27. Keck PE Jr, McElroy SL, Strakowski SM, et al. 1996. Factors associated with pharmacologic noncompliance in patients with mania. J Clin Psychiatry, 57:292-7.
28. Kessler RC, Chiu WT, Demler O, et al. 2005. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry, 62:617-27.
29. Ketter TA, Kalali AH, Weisler RH, et al. 2004. A 6-month, multicenter, open-label evaluation of extended-release carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry, 65:668-73.
30. Kleindienst N, Greil W. 2000. Differential efficacy of lithium and carbamazepine in the prophylaxis of bipolar disorder: results of the MAP study. Neuropsychobiology, 42(Suppl 1):2-10.
31. Li X, Ketter TA, Frye MA. 2002. Synaptic, intracellular, and neuroprotective mechanisms of anticonvulsants: are they relevant for the treatment and course of bipolar disorders? J Affect Disord, 69:1-14.
32. McElroy SL, Keck PE Jr. 2000. Pharmacologic agents for the treatment of acute bipolar mania. Biol Psychiatry, 48:539-57.
33. McLean A, Browne S, Zhang Y, et al. 2001. The influence of food on the bioavailability of a twice-daily controlled release carbamazepine formulation. J Clin Pharmacol, 41:183-6.
34. Miller AD, Krauss GL, Hamzeh FM. 2004b. Improved CNS tolerability following conversion from immediate- to extended-release carbamazepine. Acta Neurol Scand, 109:374-7.
35. Mitchell PB, Malhi GS. 2002. The expanding pharmacopoeia for bipolar disorder. Annu Rev Med, 53:173-88.
36. Montgomery SA, Schatzberg AF, Guelfi JD, et al. 2000. Pharmacotherapy of depression and mixed states in bipolar disorder. J Affect Disord, 59(Suppl 1):S39-56.
37. Muller-Oerlinghausen B, Berghofer A, Bauer M. 2002. Bipolar disorder. Lancet, 359:241-7.
38. Okuma T, Kishimoto A, Inoue K, et al. 1973. Anti-manic and prophylactic effects of carbamazepine (Tegretol) on manic depressive psychosis. A preliminary report. Folia Psychiatr Neurol Jpn, 27:283-97.
39. Okuma T, Yamashita I, Takahashi R, et al. 1990. Comparison of the antimanic efficacy of carbamazepine and lithium carbonate by double-blind controlled study. Pharmacopsychiatry, 23:143-50.
40. Pellock JM. 1987. Carbamazepine side effects in children and adults. Epilepsia, 28(Suppl 3):S64-70.
41. Riva R, Albani F, Ambrosetto G, et al. 1984. Diurnal fluctuations in free and total steady-state plasma levels of carbamazepine and correlation with intermittent side effects. Epilepsia, 25:476-81.
42. Shire US Inc. 2005. Equetro (™) [Prescribing information].
43. Small JG, Klapper MH, Milstein V, et al. 1991. Carbamazepine compared with lithium in the treatment of mania. Arch Gen Psychiatry, 48: 915-21.
44. Stevens RE, Limsakun T, Evans G, et al. 1998. Controlled, multidose, pharmacokinetic evaluation of two extended- release carbamazepine formulations (Carbatrol and Tegretol-XR). J Pharm Sci, 87:1531-4.
45. Stimmel GL. 2004. Economic grand rounds: the economic burden of bipolar disorder. Psychiatr Serv, 55:117-18.
46. Suppes T, Dennehy EB, Hirschfeld RM, et al. 2005. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry, 66:870-86.
47. Svarstad BL, Shireman TI, Sweeney JK. 2001. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv, 52:805-11.
48. Ulrich ML, Rotzinger S, Asghar SJ, et al. 2003. Effects of dextroamphetamine, lithium chloride, sodium valproate and carbamazepine on intraplatelet Ca2+ levels. J Psychiatry Neurosci, 28:115-25.
49. Vasudev K, Goswami U, Kohli K. 2000. Carbamazepine and valproate monotherapy: feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder. Psychopharmacology (Berl), 150:15-23.
50. Weisler RH, Hirschfeld R, Cutler AJ, et al. 2004a. Efficacy of extended-release carbamazepine in bipolar disorder: results of two pooled clinical trials. US Psychiatric and Mental Health Congress. 2004 November 18-21; San Diego, CA, USA.
51. Weisler RH, Hirschfeld R, Cutler AJ, et al. 2004b. Safety and tolerability of extended-release carbamazepine in bipolar disorder: results from 2 pooled clinical trials. US Psychiatric and Mental Health Congress. 2004 November 18-21; San Diego, CA, USA.
52. Weisler RH, Kalali AH, Ketter TA, et al. 2004c. A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry, 65:478-84.
53. Weisler RH, Keck PE, Swann AC, et al. 2005. Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry, 66:323-30.
54. [WHO] World Health Organization. 2004. Gender in mental health research. Geneva:WHO.
55. Wyatt RJ, Henter I. 1995. An economic evaluation of manic-depressive illness - 1991. Soc Psychiatry Psychiatr Epidemiol, 30:213-19.